Sam Tetlow Email & Phone Number

New York, NY, US

Durham, North Carolina, US

At Grant Engine we are entrepreneurs ourselves and know how to build companies. We apply this necessary expertise to securing grants from NIH, DoD and other sources. After developing my last two companies on grant funding from NIH and the DoD, combined with equity, I launched the platform Grant Engine about 4 years ago. With win rates at 2 to 4x better.

Greenville, NC, US

Amalgent is a clinical-stage pain management company that is developing its first oral combination therapeutics for the US market. We understand that severe pain is a global challenge and that existing medications provide patients and their families with inadequate care. Amalgent is developing combination drugs that dramatically reduce the doses required.

Growing Neurodiversity. PrimeNeuro is building smart software for early diagnosis, intervention, and management in developmental disabilities, including tools to support parents as they manage the chronic stress of raising a child with developmental delays. While we believe deeply in the need for research and products to support children and adults living.

Beaverton, OR, US

Led the Board of Directors in setting strategy, providing resources for CEO and Team, and ensure effective corporate governance. Support execution of business strategy as Chief Business Officer. Led fundraising of $1.9 million (Fall, 2015) of successful NIH grants that enabled initial full-time management to join. Recruited company's first CEO (Oct, 2015)..

Durham, North Carolina, US

Establish vision and strategy for company. Oversee operational execution, strategic partnership development, fundraising, recruiting, and allocation of capital for leading epigenetics firm. Led company from early revenue through cash flow positive operations. * Lead team of seventeen science and operations personnel. Negotiated key licenses for IP and.

Identified, negotiated, and closed asset purchase from Beckman Coulter Genomics into the newly formed ILS Genomics, LLC in June 2012. Once closed, I led the organization from zero revenue at purchase to annual run rate exceeding $2.5 million in the first year.

Early stage venture capital fund. Board of Director responsibility, fundraising, due diligence, deal sourcing and overall fund management.Gentris (genomics): Board member. Led investment thesis for Series A; lead RTV resource for Series B fundraising. Successfully sold one division, 8/07 and grew remaining business with industry leading growth rates..

Early stage venture capital fund. Board of Director responsibility, fundraising, due diligence, deal sourcing and overall fund management. Promoted from Associate.

Research Triangle Park, NC, US

Mr. Tetlow is responsible for working with the Chairman of the Board and the executive leadership team to set the Company’s overall strategy, and grow the business both organically and strategically. He works closely with the CEO to reinforce the company’s values across the company and expand ILS capabilities in important areas of research and medicine.

US

Respirics was purchased by Zhejiang Hisun Pharmaceutical Co Ltd, in January 2012. Respirics was a pulmonary drug delivery and development company. The company offered MD Turbo, a breath-activated accessory device for use with metered-dose inhalers, Nebulizers, Acu-Breathe single, and multi-dose dry powder inhalers. The company serves asthma and COPD.

Immunologix was purchased by Intrexon (www.dna.com) in Oct, 2011 for a successful exit within 24 months. Immunologix specializes in transforming naïve B-cells to produce 100% human monoclonal antibodies that can target all antigen types including, but not limited to cancer cells, viruses, bacteria, toxins, plus those epitopes related to autoimmune diseases.

Investment Board of Director observer. Led due diligence and co-lead for deal structuring for Series A. $26m Currently monitor investment.

Investment, Sale of Company. Continued monitoring Board of Director. Led due diligence and deal structuring for Series A. Facilitated fundraising for Series B and Series C. $8.1m Successful exit for one of two divisions (8/07). Current Board of Director.

Business Development lead for Calvert Research.

- Successful Pharmacogenomics Business Models (143 pg Industry Report; 11/03)- Outsourcing Research & Development (173 pg Industry Report; 5/04)- Pharmaceutical Industry Outlook (186 pg Industry Report; 2/05)

/04 Investment, Sale of Company. Led due diligence and co-lead for Series A. $10m Company sold to DoubleClick: 3/2004.

/06 Investment, Sale of Company. Sourced deal. Led due diligence and co-lead for deal structuring for Series A. Facilitated fundraising for Series B and Series C. $44m Company sold to Broadcom: 12/2006.

/06 Investment, Sale of Company. Took over as Interim COO and Board of Director. Led due diligence and deal structuring for Series A. Led fundraising for Series B. $4m Company sold to GCG, Inc.: 3/2006.

Acquisition Lead member of buyout team. Negotiated Purchase Agreement from Parent company. Facilitated deal structure, team equity split and organized new management team. $10m Concluded purchase agreement. Founding member of management team.

Charlotte, NC, US

Foudner. Managed strategy consulting practice. Responsible for P&L, business development, engagement delivery and pricing.Executed Exervio buy-out from marchFIRST with Exervio CEO & management. Assisted in generating revenue of $1.9 million (40% increase) and profit of $0.4 million (45% increase), in part via TARSAS software solution for major.

of Strategy. Managed strategy consulting practice. Responsible for P&L, business development, engagement delivery and pricing.Executed Exervio buy-out from marchFIRST with Exervio CEO & management. Assisted in generating revenue of $1.9 million (40% increase) and profit of $0.4 million (45% increase), in part via TARSAS software solution for major.

Manager, Finance. Directed 3-year & annual financial plan and quarterly closing process to exceed financial commitments for $1B business. Managed 8 individuals in Mexico and Charlotte.Contributed to the investment thesis, business model and realization of GE Company's first e-Commerce platform: polymerland.com.Led due diligence and acquisition of $31.

Acquisition Sourced deal opportunity, negotiated final Purchase Agreement, structured transaction, led due diligence. $31m Concluded purchase, and subsequently managed business with profit & loss responsibility.

Boston, MA, US

1998 – 2000 GE POLYMERLAND Charlotte, NCManager, Finance. Directed 3-year & annual financial plan and quarterly closing process to exceed financial commitments for $1B business. Managed 8 individuals in Mexico and Charlotte.Senior Financial Analyst. Lead role in product line profitability analysis, base cost management and foreign exchange hedging..

Boston, MA, US

Conducted operational and financial reviews on global 4-month rotations on behalf of Office of the Chairman. Emphasis on leadership development via strategic reviews and business unit financial verification. Conducted M&A due diligence with cross-functional team on Philippine Airlines ($50 million, Manila) and Danje Polymers ($15 million, Warsaw). Achieved.

Acquisition Negotiated final Purchase Agreement, via structured transaction. Led due diligence. $15m Concluded purchase. Instrumental in integrating the business into GE Polymerland.

Acquisition Led due diligence. Drove deal negotiation and facilitated consummation of the acquisition. $50m Concluded purchase. Instrumental in integrating the business into GE Engine Services.

Technical Leadership Program. Two-year training program on six month rotations in multiple functions and responsibilities. Promoted from proposal sales manager in 1994. Completed proposals and contributed to deal signing for Akzo Nobel ($350m) & Central Jersey Power & Light ($150m).Managed long-term customer relationships ranging in size from $35m.

Mba, Venture Capital & Entrepreneurship

B.S., Aerospace Engineering